PMC:7441788 / 19295-19516 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T103","span":{"begin":203,"end":211},"obj":"Disease"}],"attributes":[{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":": n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T235","span":{"begin":75,"end":80},"obj":"Chemical"},{"id":"T236","span":{"begin":117,"end":122},"obj":"Chemical"}],"attributes":[{"id":"A235","pred":"chebi_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A236","pred":"chebi_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":": n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients "}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T105","span":{"begin":203,"end":211},"obj":"Species"}],"attributes":[{"id":"A105","pred":"ncbi_taxonomy_id","subj":"T105","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":": n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients "}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"647","span":{"begin":212,"end":220},"obj":"Species"},{"id":"682","span":{"begin":10,"end":13},"obj":"Chemical"},{"id":"683","span":{"begin":71,"end":74},"obj":"Chemical"},{"id":"684","span":{"begin":113,"end":116},"obj":"Chemical"},{"id":"685","span":{"begin":124,"end":127},"obj":"Chemical"},{"id":"713","span":{"begin":175,"end":184},"obj":"Disease"},{"id":"714","span":{"begin":188,"end":202},"obj":"Disease"},{"id":"715","span":{"begin":203,"end":211},"obj":"Disease"}],"attributes":[{"id":"A715","pred":"pubann:denotes","subj":"715","obj":"MESH:C000657245"},{"id":"A647","pred":"pubann:denotes","subj":"647","obj":"Tax:9606"},{"id":"A714","pred":"pubann:denotes","subj":"714","obj":"MESH:D016638"},{"id":"A685","pred":"pubann:denotes","subj":"685","obj":"MESH:D006886"},{"id":"A682","pred":"pubann:denotes","subj":"682","obj":"MESH:D006886"},{"id":"A683","pred":"pubann:denotes","subj":"683","obj":"MESH:D006886"},{"id":"A684","pred":"pubann:denotes","subj":"684","obj":"MESH:D006886"},{"id":"A713","pred":"pubann:denotes","subj":"713","obj":"MESH:D003643"}],"text":": n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients "}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T96","span":{"begin":203,"end":211},"obj":"Disease"}],"attributes":[{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":": n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients "}

{"project":"LitCovid-PubTator","denotations":[{"id":"647","span":{"begin":212,"end":220},"obj":"Species"},{"id":"682","span":{"begin":10,"end":13},"obj":"Chemical"},{"id":"683","span":{"begin":71,"end":74},"obj":"Chemical"},{"id":"684","span":{"begin":113,"end":116},"obj":"Chemical"},{"id":"685","span":{"begin":124,"end":127},"obj":"Chemical"},{"id":"713","span":{"begin":175,"end":184},"obj":"Disease"},{"id":"714","span":{"begin":188,"end":202},"obj":"Disease"},{"id":"715","span":{"begin":203,"end":211},"obj":"Disease"}],"attributes":[{"id":"A647","pred":"tao:has_database_id","subj":"647","obj":"Tax:9606"},{"id":"A682","pred":"tao:has_database_id","subj":"682","obj":"MESH:D006886"},{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"MESH:D006886"},{"id":"A684","pred":"tao:has_database_id","subj":"684","obj":"MESH:D006886"},{"id":"A685","pred":"tao:has_database_id","subj":"685","obj":"MESH:D006886"},{"id":"A713","pred":"tao:has_database_id","subj":"713","obj":"MESH:D003643"},{"id":"A714","pred":"tao:has_database_id","subj":"714","obj":"MESH:D016638"},{"id":"A715","pred":"tao:has_database_id","subj":"715","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":": n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients "}